In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and more. Read the full coverage here: Addition of immunotherapy to chemotherapy improves survival rates of infants with leukemia Extreme poverty linked to nearly twofold higher risk for relapse among children with ALL FDA approves allogeneic cell therapy Omisirge for patients with blood cancers Vaping linked to cancer-related cognitive impairment among young adult cancer survivors Intervention reduces financial toxicity among people with blood cancers References: Healio Interview Ng DQ, et al. JCO Oncol Pract. 2023;doi:10.1200/op.22.00458. Press Release van der Sluis IM, et al. N Eng J Med. 2023;doi:10.1056/NEJMoa2214171. Wadhwa A, et al. Blood. 2023;doi:10.1182/blood.2023019631.

Ver todos los episodios